AU2019223168B2 - EGFR dimer disruptors and use of the same - Google Patents
EGFR dimer disruptors and use of the same Download PDFInfo
- Publication number
- AU2019223168B2 AU2019223168B2 AU2019223168A AU2019223168A AU2019223168B2 AU 2019223168 B2 AU2019223168 B2 AU 2019223168B2 AU 2019223168 A AU2019223168 A AU 2019223168A AU 2019223168 A AU2019223168 A AU 2019223168A AU 2019223168 B2 AU2019223168 B2 AU 2019223168B2
- Authority
- AU
- Australia
- Prior art keywords
- egfr
- compound
- equiv
- dgd1202
- reaction mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634452P | 2018-02-23 | 2018-02-23 | |
| US62/634,452 | 2018-02-23 | ||
| PCT/US2019/019391 WO2019165358A1 (en) | 2018-02-23 | 2019-02-25 | Egfr dimer disruptors and use of the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019223168A1 AU2019223168A1 (en) | 2020-09-10 |
| AU2019223168B2 true AU2019223168B2 (en) | 2024-09-12 |
Family
ID=67688515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019223168A Active AU2019223168B2 (en) | 2018-02-23 | 2019-02-25 | EGFR dimer disruptors and use of the same |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11358965B2 (https=) |
| EP (1) | EP3755323A4 (https=) |
| JP (2) | JP7497046B2 (https=) |
| KR (1) | KR102748047B1 (https=) |
| CN (1) | CN111886009A (https=) |
| AU (1) | AU2019223168B2 (https=) |
| BR (1) | BR112020017184A2 (https=) |
| CA (1) | CA3091834A1 (https=) |
| EA (1) | EA202092000A1 (https=) |
| MX (1) | MX2020008767A (https=) |
| WO (1) | WO2019165358A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3091834A1 (en) * | 2018-02-23 | 2019-08-29 | The Regents Of The University Of Michigan | Egfr dimer disruptors and use of the same |
| CN114286676A (zh) * | 2019-08-22 | 2022-04-05 | 密歇根大学董事会 | 治疗kras相关癌症的方法 |
| CA3172812A1 (en) * | 2020-03-05 | 2021-09-10 | The Regents Of The University Of Michigan | Inhibitors of egfr, kras, braf, and other targets and use of the same |
| MX2022010977A (es) * | 2020-03-05 | 2022-12-02 | Univ Michigan Regents | Inhibidores de egfr, kras, braf y otros objetivos y uso de los mismos. |
| IL301532A (en) | 2020-09-23 | 2023-05-01 | Scorpion Therapeutics Inc | History Pyrrolo[2,3-C]pyridin-4-one is useful in cancer treatment |
| WO2022072632A1 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Bicyclic compounds for use in the treatment cancer |
| WO2022072645A2 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| TW202229282A (zh) | 2020-09-30 | 2022-08-01 | 美商史考皮恩治療有限公司 | 治療癌症之方法 |
| BR112023006531A2 (pt) | 2020-10-09 | 2023-10-03 | Scorpion Therapeutics Inc | Inibidores heterocílicos de egfr e/ou her2, para uso no tratamento de câncer |
| EP4225304B1 (en) * | 2020-10-12 | 2025-12-17 | The Regents of The University of Michigan | Synthesis of egfr modulators |
| WO2022077154A1 (en) * | 2020-10-12 | 2022-04-21 | The Regents Of The University Of Michigan | Synthesis of egfr modulators |
| WO2022094271A1 (en) | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022098992A1 (en) | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| WO2022197913A1 (en) | 2021-03-18 | 2022-09-22 | Scorpion Therapeutics, Inc. | Bicyclic derivatives which can be used to treat cancer |
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| WO2023173083A1 (en) | 2022-03-11 | 2023-09-14 | Scorpion Therapeutics, Inc. | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer |
| CN121909190A (zh) | 2023-06-08 | 2026-04-21 | 安塔列斯疗法股份有限公司 | 1,5-二氢-4H-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗 |
| CN121712773A (zh) | 2023-06-08 | 2026-03-20 | 安塔列斯疗法股份有限公司 | 1,5-二氢-4h-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3547977A (en) | 1967-10-27 | 1970-12-15 | Velsicol Chemical Corp | Novel carbanilates |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2012087943A2 (en) | 2010-12-20 | 2012-06-28 | The Regents Of The University Of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
| WO2014176475A2 (en) * | 2013-04-26 | 2014-10-30 | The Regents Of The University Of Michigan | Egfr inhibitors and uses thereof |
| US9499551B2 (en) * | 2014-01-24 | 2016-11-22 | Confluence Life Sciences, Inc. | Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases |
| CN113563332B (zh) * | 2014-12-23 | 2024-12-17 | 达纳－法伯癌症研究所公司 | 作为egfr抑制剂的新的嘧啶和治疗病症的方法 |
| CA3091834A1 (en) | 2018-02-23 | 2019-08-29 | The Regents Of The University Of Michigan | Egfr dimer disruptors and use of the same |
-
2019
- 2019-02-25 CA CA3091834A patent/CA3091834A1/en active Pending
- 2019-02-25 EP EP19757355.3A patent/EP3755323A4/en active Pending
- 2019-02-25 MX MX2020008767A patent/MX2020008767A/es unknown
- 2019-02-25 WO PCT/US2019/019391 patent/WO2019165358A1/en not_active Ceased
- 2019-02-25 US US16/970,655 patent/US11358965B2/en active Active
- 2019-02-25 KR KR1020207027147A patent/KR102748047B1/ko active Active
- 2019-02-25 EA EA202092000A patent/EA202092000A1/ru unknown
- 2019-02-25 CN CN201980020234.3A patent/CN111886009A/zh active Pending
- 2019-02-25 JP JP2020544510A patent/JP7497046B2/ja active Active
- 2019-02-25 AU AU2019223168A patent/AU2019223168B2/en active Active
- 2019-02-25 BR BR112020017184-0A patent/BR112020017184A2/pt unknown
-
2022
- 2022-05-09 US US17/739,358 patent/US11999731B2/en active Active
-
2024
- 2024-01-25 JP JP2024009496A patent/JP2024056735A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200124709A (ko) | 2020-11-03 |
| BR112020017184A2 (pt) | 2020-12-22 |
| EA202092000A1 (ru) | 2020-12-09 |
| US20200377503A1 (en) | 2020-12-03 |
| WO2019165358A1 (en) | 2019-08-29 |
| AU2019223168A1 (en) | 2020-09-10 |
| CN111886009A (zh) | 2020-11-03 |
| US20220340572A1 (en) | 2022-10-27 |
| EP3755323A1 (en) | 2020-12-30 |
| JP7497046B2 (ja) | 2024-06-10 |
| EP3755323A4 (en) | 2021-11-24 |
| JP2024056735A (ja) | 2024-04-23 |
| US11999731B2 (en) | 2024-06-04 |
| CA3091834A1 (en) | 2019-08-29 |
| MX2020008767A (es) | 2021-01-08 |
| US11358965B2 (en) | 2022-06-14 |
| KR102748047B1 (ko) | 2024-12-27 |
| JP2021514001A (ja) | 2021-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019223168B2 (en) | EGFR dimer disruptors and use of the same | |
| ES2632241T3 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos | |
| TWI733679B (zh) | Ｈｐｋ１抑制劑及其使用方法 | |
| CN108602821B (zh) | 1h-咪唑并[4,5-b]吡啶基bet溴结构域抑制剂 | |
| AU2021230372A1 (en) | Inhibitors of EGFR, KRAS, BRAF, and other targets and use of the same | |
| WO2018033815A1 (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
| CA3068854A1 (en) | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase | |
| AU2021230553A1 (en) | Inhibitors of EGFR, KRAS, BRAF, and other targets and use of the same | |
| RS65884B1 (sr) | Makrociklična jedinjenja i primene istih | |
| CN111153899A (zh) | 一种取代吡啶化合物、其制备方法和用途 | |
| WO2016055479A1 (en) | Tetrahydroisoquinoline derivatives | |
| AU2007276788A1 (en) | Compounds and compositions as hedgehog signaling pathway modulators | |
| CA3177022A1 (en) | Compounds and methods for yap/tead modulation and indications therefor | |
| WO2024129634A1 (en) | Rbm39 sulfonamide inhibitors | |
| CA3233398A1 (en) | Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer | |
| EA042609B1 (ru) | Ингибиторы димеризации egfr и их использование | |
| HK40034660A (en) | Egfr dimer disruptors and use of the same | |
| HK40057478B (zh) | Hpk1抑制剂及其使用方法 | |
| EP4729515A1 (en) | New acylsulfonamide derivatives and their use for the treatment of cancer | |
| HK1263053A1 (en) | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |